King, Valerie A.

From: Roethig, Hans

Sent: Monday, December 29, 2003 8:47 AM

To: Zedler, Barbara; Gogova, Maria; King, Valerie A.; Kinser, Robin D.; Mawyer, Denise T.; Mendes, Paul; Oey, Jan; Sarkar, Mohamadi; Unverdorben, Martin; Prchal, Kimberly M [MDS Pharma Services]

Subject: RE: final CE Clin Process re Unused Study Product Destruction

Sensitivity: Confidential

DSS:

Dear Barbara,
I would consider the draft report a better time point to destroy the investigational product. If you want to do any retesting based on the results of the study you are not able to do it.
So in general I agree that the closure of the db is the minimum time needed but the draft report seems to be a better point from my point of view. If everybody agrees you may add this as the preferred option and leave the closure of the db as the minimum time.

Best regards
Hans

-----Original Message-----
From: Zedler, Barbara
Sent: Tuesday, December 23, 2003 4:00 PM
To: Gogova, Maria; King, Valerie A.; Kinser, Robin D.; Mawyer, Denise T.; Mendes, Paul; Oey, Jan; Roethig, Hans; Sarkar, Mohamadi; Unverdorben, Martin; Prchal, Kimberly M [MDS Pharma Services]
Subject: final CE Clin Process re Unused Study Product Destruction
Sensitivity: Confidential

fyi. Study mgrs, pls implement for ongoing studies as applicable, and for all future studies.

Barb

Barbara K. Zedler, M.D.
Director, Clinical Operations
Clinical Evaluation
Worldwide Scientific Affairs
Philip Morris USA
Richmond, VA
barbara.k.zedler@pmusa.com
804.274.2799
cell 804.366.5600

PM3006735531

Source: https://www.industrydocuments.ucsf.edu/docs/pmpx0001